pantoprazole has been researched along with rivaroxaban in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (50.00) | 24.3611 |
| 2020's | 3 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Commerford, PJ; Connolly, SJ; Cook Bruns, N; Dagenais, GR; Dans, A; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, T; Hart, RG; Hori, M; Kakkar, A; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, K; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J | 1 |
| Alings, M; Anand, SS; Avezum, A; Bhatt, DL; Bosch, J; Branch, KRH; Bruns, NC; Commerford, PJ; Connolly, SJ; Dagenais, GR; Dans, AL; Diaz, R; Dyal, L; Eikelboom, JW; Ertl, G; Felix, C; Fox, KAA; Guzik, TJ; Hart, RG; Hori, M; Kakkar, AK; Keltai, M; Kim, JH; Lanas, F; Leong, D; Lewis, BS; Liang, Y; Lonn, EM; Lopez-Jaramillo, P; Maggioni, AP; Metsarinne, KP; Moayyedi, P; Muehlhofer, E; O'Donnell, M; Parkhomenko, AN; Piegas, LS; Pogosova, N; Probstfield, J; Ryden, L; Shestakovska, O; Steg, PG; Störk, S; Tonkin, AM; Torp-Pedersen, C; Verhamme, PB; Vinereanu, D; Widimsky, P; Yusoff, K; Yusuf, S; Zhu, J | 1 |
| Borzak, S; Dayanand, P | 1 |
| Eikelboom, JW; Moayyedi, P; Yusuf, S | 1 |
| Bronswijk, M | 1 |
| Donzelli, A; Giudicatti, G | 1 |
2 trial(s) available for pantoprazole and rivaroxaban
| Article | Year |
|---|---|
Pantoprazole to Prevent Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin in a Randomized, Double-Blind, Placebo-Controlled Trial.
Topics: Administration, Oral; Aged; Anticoagulants; Aspirin; Cardiovascular Diseases; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pantoprazole; Peptic Ulcer; Proton Pump Inhibitors; Rivaroxaban; Treatment Outcome | 2019 |
Safety of Proton Pump Inhibitors Based on a Large, Multi-Year, Randomized Trial of Patients Receiving Rivaroxaban or Aspirin.
Topics: Aged; Aspirin; Cardiovascular Diseases; Double-Blind Method; Drug Administration Schedule; Enterocolitis, Pseudomembranous; Factor Xa Inhibitors; Female; Gastrointestinal Hemorrhage; Humans; Male; Middle Aged; Pantoprazole; Peripheral Arterial Disease; Platelet Aggregation Inhibitors; Prospective Studies; Proton Pump Inhibitors; Risk Assessment; Risk Factors; Rivaroxaban; Time Factors; Treatment Outcome | 2019 |
4 other study(ies) available for pantoprazole and rivaroxaban
| Article | Year |
|---|---|
Pantoprazole did not reduce risk for a composite of upper gastrointestinal events in stable arterial disease.
Topics: Aspirin; Double-Blind Method; Humans; Pantoprazole; Proton Pump Inhibitors; Rivaroxaban | 2019 |
Reply.
Topics: Aspirin; Double-Blind Method; Humans; Pantoprazole; Rivaroxaban | 2020 |
Pantoprazole in Prevention of Gastroduodenal Events in Patients Receiving Rivaroxaban and/or Aspirin-A Short Word of Caution.
Topics: Aspirin; Double-Blind Method; Factor Xa Inhibitors; Humans; Pantoprazole; Platelet Aggregation Inhibitors; Rivaroxaban | 2020 |
Pantoprazole in COMPASS- No Prevention of Gastroduodenal Events or Other Useful Net Results.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Aspirin; Double-Blind Method; Humans; Pantoprazole; Rivaroxaban | 2020 |